AI assistant
Equillium, Inc. — Director's Dealing 2025
Feb 20, 2025
34270_dirs_2025-02-19_79904713-4ed4-4de9-ac47-2bb28228ba5e.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Equillium, Inc. (EQ)
CIK: 0001746466
Period of Report: 2025-02-14
Reporting Person: Troupin Barbara (N/A)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2025-02-14 | Director Stock Option (right to buy) | $0.785 | A | 40000 | Acquired | 2032-02-29 | Common Stock (40000) | Direct |
| 2025-02-14 | Director Stock Option (right to buy) | $3.59 | D | 40000 | Disposed | 2032-02-29 | Common Stock (40000) | Direct |
Footnotes
F1: The option vests in 36 equal monthly installments following the grant date of March 1, 2022.
F2: On August 7, 2023, the Board of Directors of the Company approved the repricing of certain options based on the closing price of the Company's common stock on August 14, 2023. The repricing of these options was subject to a holding period that lapsed on February 14, 2025. The repricing resulted in the impacted options having a lower exercise price of $0.785 per share, which is the closing price of the Company's common stock on the Nasdaq Capital Market on August 14, 2023. All of the other terms of the options remained unchanged.